Pain drug research gains momentum a year after Vertex launch as new startups revive sodium channel targets

A year after Vertex introduced its breakthrough pain medication, the field of pain drug development is at a pivotal crossroads. Analysts note that renewed scientific focus and investor interest are reshaping expectations for future therapies.

In 2019, Amgen largely withdrew from brain‑focused drug research, citing the high risk and cost of neuroscience projects. Many of the scientists who left Amgen found positions at a new venture created by Westlake BioPartners, a firm that quickly moved to explore the same challenging area.

The Westlake‑backed startup is targeting sodium ion channels-tiny structures on cell membranes that play a key role in pain signaling. After years of difficult experimentation, the company reports promising early data, rekindling enthusiasm among investors looking for the next breakthrough in pain management.